COMPOSITIONS AND METHODS FOR TREATMENT OF CANCERS USING MODIFIED siRNA-GEM AGENTS
AssigneeSirnaomics, Inc.
InventorsDavid M. EVANS, Daniel MUTISYA, Sean LU, Bhaskar HALAMI, Vera SIMONENKO
Life of this patent
Estimating the term…
Loading patent…
AssigneeSirnaomics, Inc.
InventorsDavid M. EVANS, Daniel MUTISYA, Sean LU, Bhaskar HALAMI, Vera SIMONENKO
Estimating the term…
Pharmaceutical compositions are provided comprising gemcitabine (“GEM”)-containing modified RNAi agents such as siRNA molecules, combined with a histidine-lysine copolymer carrier, intended for inhibiting the expression of targeted genes involved in a variety of cancers. Modifications to the siRNA backbone may include, without limitation, 2′-OMe, 2′-Fluoro and phosphorothioate modifications. Methods for treatment of a variety of cancers by administering such pharmaceutical compositions are further provided, including breast, ovarian, and pancreatic cancer in mammals, among others.
A pharmaceutical composition comprising a modified, interfering ribonucleic acid (RNAi) molecule combined with one or more gemcitabine molecules in the place of cytidine molecules, and further comprises a histidine-lysine copolymer carrier, wherein the RNAi is selected from the group consisting of siRNA, miRNA, and shRNA and mRNA.
A method of treating a subject having cancer, comprising:
A method of treating a subject having cancer comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising at least one RNAi molecule selected from the group consisting of SEQ ID Nos. 7-8, SEQ ID Nos. 9-10, SEQ ID No. 13 and SEQ. ID No. 14, wherein the composition further comprises HKP(+H) and wherein the pharmaceutical composition is administered through intravenous or intratumoral injection.
Dependencies are inferred from the claim text.